U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	ite for form 1449B/PTO	Compl te if Known		
INFORM	ATION DISCLOSURE	Application Number	10/419,059	
PE COSSTATEN	ENT BY APPLICANT	Filing Dat	04/17/2003	
		First Named Inventor	Kenneth F. Buechler	
		Group Art Unit	' Unassigned	
(use many sheets as necessary)		Examiner Name	Unassigned	
Sheet 🐉	of, 8	Attorney Docket Number	071949-7001	

		U.S. Patent	Document			Pages, Columns, Lines,	
Examine Initials*	r Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
LYL A1 5,480,792			Buechler et al.	Jan. 2, 1996			
	A2	5,525,524		Buechler et al.	June 11, 1996	-	
<u> </u>	A3	5,571,698		Ladner et al.	Nov. 5, 1996		
	· A4	5,631,171		Sandstrom et al. /	May 20, 1997		
	A5	5,679,526		Buechler et al. ·.	Oct. 21, 1997		
	A6	5,719,060		Hutchens et al.	Feb. 17, 1998		
	A7	5,824,799		Buechler et al.	Oct. 20, 1998		
	A8	5,851,776		Valkirs	Dec. 22, 1998		
	A9	5,885,527		Buechler	March 23, 1999		
	A10	5,894,063		Hutchens et al.	Apr. 13, 1999		
	A11	5,922,615		Nowakowski et al.	July 13, 1999		
	A12	5,939,272		Buechler et al.	Aug. 17, 1999		
	A13	5,947,124		Buechler et al.	Sept. 7, 1999		
	A14	5,955,377		Maul et al.	Sept. 21, 1999		
	A15	5,985,579		Buechler et al.	Nov. 16, 1999		
	A16	6,019,944		Buechler	Feb. 1, 2000		
	A17	6,020,208		Hutchens et al.	Feb. 1, 2000		
	A18	6,027,942		Hutchens et al.	Feb. 22, 2000		
	A19	6,057,098		Buechler et al.	May 2, 2000		
	A20	6,107,623		Bateman et al.	Aug. 22, 2000		
	A21	6,113,855		Buechler	Sept. 5, 2000		
	A22	6,124,137		Hutchens et al.	Sept. 26, 2000		
	A23	6,143,576	<u> </u>	Buechler	Nov. 7, 2000	•	
	A24	6,204,500		Whitehouse et al.	March 20, 2001		
\Box	A25	6,225,047		Hutchens et al.	May 1, 2001		
LYL	A26	6,268,144		Koster	July 31, 2001		

Examiner Initials*	Cite No.1	Office	oreign Patent D 3 Number4	ocument Kind Cod (if known)	The production of the control of the	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
· LYL	A27	wo	O2/083913		Biosite Diagnostics, Inc.	Oct. 24, 2002		1
146	A28	WO	02/089657		Biosite, Inc.	Nov. 14, 2002		1
LYL	A29	WO	03/016910	` _	Biosite, Inc.	Feb. 27, 2003		1

		<u>, </u>	
Examiner Signature	I KK	Date Considered	7/19/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute fo	r form 1449B/P	oto	OIPE		Complete if Known	
	INFORMATIO	ON DISCLOS	URE	0 -	Applicati n Numb r	10/419,059	···-
	STATEMEN'	T BY APPLIC	ANT		kiling Dat	04/17/2003	
			L N	IOV 1 2 2000	First Named Inv. ntor	Kenneth F. Buechler	
			E	- 600	Group Art Unit	Unassigned	
	(use as many s	heets as nec	essary)		Examiner Name	Unassigned	·····
Sheet	2	of	8 Kg	D	Attorney Docket Number	071949-7001	:

=		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
CYL	A30 Bonow, R.O., "New insights into the cardiac natriuretic peptides." Circulation 93:1946-1950, (19		
1	A31	Cagney and Emili, "De novo peptide sequencing and quantitative profiling of complex protein mixtures	+-
		using mass-coded abundance tagging." Nature Biotechnol. 20: 163-170, (2002).	;
	A32	Cannon et al., *Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial	+
		infarction following treatment with Tirofiban: Rationale and study design of the international TACTICS-TIMI	1:
		18 trial." Am. J. Cardiol. 82: 731-6, (1998)	
	A33	Cheng et al., "A Rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for	1
		decompensated heart failure: A pilot study." J. Am. Coll. Cardiol. 37: 386-91, (2001).	
	A34	Cho et al., "Natriuretic peptides and their therapeutic potential." Heart Dis. 1: 305-28, (1999).	<u> </u>
	A35	Cwirla et al., *Peptides on phage: A vast library of peptides for identifying ligands." <i>Proc. Natl. Acad. Sci. USA</i> 87, 6378-82, (1990).	-
	A36	Davidson et al., "C-Type natriuretic peptide." Circulation 93:1155-9, (1996).	
iyl	A37	Devlin et al., "Random peptide libraries: A source of specific protein binding molecules." Science 249, 404-6, (1990).	-

Examiner Signature	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. Emter Office that issued the document, by the two-letter code (WIPO Standard ST.3). °For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. °Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are number.

Substitute for form 14498(P) Complet if Known INFORMATION DISCLOSURE 10/419,059 Application Numb r. STATEMENT BY APPLICANT 04/17/2003 **Filing Date** First Named Inventor. Kenneth F. Buechler Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet Attorney Docket Number 071949-7001

		NON PATENT LITERATURE DOCUMENTS	***************************************						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	76						
LYL A38		Fischer et al., "Evaluation of a new, rapid bedside test for quantitative determination of B-Type natriuretic							
ĺ		peptide.* Clin. Chem. 47: 591-594, (2001).							
	A39	Gobinet-Georges et al. "Stability of brain natriuretic peptide (BNP) in human whole blood and plasma." Clin.	:						
		Chem. Lab. Med. 38: 519-23, (2000).							
	A40	Hamm et al., "Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin	ļ.						
	740	T levels." N. Engl. J. Med. 340; 1623-9, (1999).							
	A41	Hartree, "Determination of protein: A modification of the lowry method that gives a linear photometric							
		response." Anal Biochem 48: 422-427, (1972).	:						
	A42	Hunt et al., "The role of the circulation in processing pro-Brain natriuretic peptide (proBNP) to aminoterminal BNP and BNP-32." Biochem. Biophys. Res. Comm. 214: 1175-83, (1995).	· : • :						
			:						
	A43	Hunt et al., "The amino-terminal portion of pro-Brain natriuretic peptide (Pro-BNP) circulates in human plasma." Peptides 18: 1475-81, (1997).							
			: •						
. 	A44	Huse et al., "Application of a Filamentous phage pVII fusion protein system suitable for efficient production,	<u>;</u>						
LYL		screening, and mutagenesis of F(ab) antibody fragments." Journal of Immunology, 140: 3914-3920, (1992).	:						

Examiner Signature	LK	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

NOV 1 2 2003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 199 and persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for for	m 1449B	PROPRIEME	ary		Compl te if Known	
	INFORMATION	DISCLO	SURE		Application Numb r	10/419,059	
	STATEMENT B	Y APPLI	CANT		Filing Dat	04/17/2003	
					First Nam d Inv ntor	Kenneth F. Buechler	:
					Group Art Unit	Unassigned	
	(use as many shee	ts as ne	cessary)		Examiner Name	Unassigned	
Sheet	4	of	8		Attomey Docket Number	071949-7001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
11/1	A45	Issaq et al., "SELDI-TOF MS for diagnostic proteomics." Anal. Chem. 75: 149A-155A, (2003).	
LYL			1.
			1.
	A46	Issaq et al., "The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification."	1
		Biochem. Biophys. Res. Commun. 292: 587-92, (2002).	
l			į
			1:
	A47 .	Kalra et al., "Myocardial production of C-Type natriuretic peptide in chronic heart failure." Circulation 107:	
		571-3, (2003).	
-			
			1
	A48	Lowry et al., "Protein measurement with the folin phenol reagent." J. Biol. Chem. 193: 265, (1951).	
-			
i i	A49	Merchant and Weinberger, "Recent advancements in surface-enhanced laser desorption/ionization-time of	
		flight-mass spectrometry." Electrophoresis 21: 1164-67, (2000).	1.
_	A50	Marrow of al. "Cording transpire Lifer stratification of and and and the fifth	<u> :</u>
1	A00	Morrow et al., "Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in	
176		unstable angina: A TIMI-11B substudy." J. Am. Coll. Cardiol. 36: 1812-7, (2000).	:
.616			
			<u> </u>
			1

Examiner Signature Date Con:	nte 7//	19/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/P Compl te if Known INFORMATION DISCLOSURE **Application Number** 10/419,059 STATEMENT BY APPLICANT 04/17/2003 Filing Dat First Named Inv ntor Kenneth F. Buechler Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 8 Attorney Docket Number 071949-7001

		NON PATENT LITERATURE DOCUMENTS		
Examiner nitials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number publisher, city and/or country where published.			
	A51	Motwani et al., "Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme	+	
CYL		inhibition after myocardial infarction." Lancet 341: 1109-13, (1993).		
- 1				
	A52	Murdoch et al. "Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid	Ť	
		assay: Implications for clinical practice." Heart 78: 594-7, (1997).	ŀ	
			ŀ	
	A53	Ng and Ilag, "Biomedical applications of protein chips." J. Cell Mol. Med. 6: 329-340, (2002).	T	
1				
1			:	
			:	
1	A54	Norman et al. "Degradation of brain natriuretic peptide by neutral endopeptidase: Species specific sites of		
ŀ		proteolysis determined by mass spectrometry." Biochem. Biophys. Res. Commun. 28: 175: 22-30, (1991).		
1				
:]			1	
			1	
1	A55	Prickett et al., "Identification of amino-terminal Pro-C-Type natriuretic peptide in human plasma." Biochem.		
LYL		Biophys. Res. Commun. 286:513-7, (2001).		
-15		•		
			1:	

		<u> </u>	
Examiner Signature	K	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control

Under the Paperwork Reduction Act of 1995,

	Substitute fo	or form 1449B	Pto		Compl te if Known	
	INFORMATI	ON DISCLO	SURBO EMARK OC	Application Number	10/419,059	
	STATEMEN	IT BY APPLI	CANT WARK!	Filing Dat	04/17/2003	
				First Nam d Inventor	Kenneth F. Buechler	
				Group Art Unit	Unassigned	
	(use as many :	sheets as ne	cessary)	Examiner Name	Unassigned	
Sheet	. 6	of	8	Attomey Docket Number	071949-7001	

niner Is*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	1	
	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.), ⊤⁵	
	A56	Ridker et al., "Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in		
1		patients with average cholesterol levels." Circulation 98: 839-44 (1998).	ŀ	
			1	
	A57	Scott and Smith, "Searching for peptide ligands with an epitope library." Science 249, 386-88, (1990).	1.	
٠			1	
			1	
			1:	
	A58	Shimizu et al., "Degradation of human brain natriuretic peptide (BNP) by contact activation of blood	1	
Ì		coagulation system." Clin. Chem. Acta 305: 181-6, (2001).	1:	
	A59	Shimizu et al., "Molecular forms of human brain natriuretic peptide in plasma." Clin. Chem. Acta 316: 129-		
\		35, (2002).	1	
			;	
			·	
	A60			
\		(2000).		
1				
+	A61	Tateyama et al., "Concentrations and molecular forms of human brain natriuretic peptide in plasma."	+	
1		·		
,			:	
1				
		A57 A58 A59 A60 A61	A57 Scott and Smith, "Searching for peptide ligands with an epitope library." Science 249, 386-88, (1990). A58 Shimizu et al., "Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system." Clin. Chem. Acta 305: 181-6, (2001). A59 Shimizu et al., "Molecular forms of human brain natriuretic peptide in plasma." Clin. Chem. Acta 316: 129-35, (2002). A60 Smith et al., "Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase." J. Endocrinol. 167: 239-46, (2000). A61 Tateyama et al., "Concentrations and molecular forms of human brain natriuretic peptide in plasma." Biochem. Biophys. Res. Commun. 185:760-7, (1992).	

Examiner Date 2/19/06		///	•			
Signature Considered 771700	Examiner Signature	XK.		Date Considered	7/19/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ¹Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

To persons are required to respond to a collection of information unless it contains a valid OMB control Under the Paperwork Reduction Act of 1995.

number.						
	Substitute f	or form 1449E	BIPTO TRADEMA	,	Complet if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Numb r	10/419,059	·
				Filing Dat	04/17/2003	
				First Nam d Inventor	Kenneth F. Buechler	
	•			Group Art Unit	Unassigned	:
	(use as many	sheets as ne	ecessary)	Examiner Name	Unassigned	
Sheet	7	of	8	Attorney Docket Number	071949-7001	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	A62	Trindade and Rouleau, "Vasopeptidase inhibitors: potential role in the treatment of heart failure." Heart Fail.					
LYL		Monit. 2: 2-7, (2001).					
j							
. /	İ		j.				
			[
	A63	Troughton et al., "Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-	-				
		BNP) concentrations." Lancet 355: 1126-30, (2000).					
	A64	Van Veldhuisen et al., "High-Versus low-dose ACE inhibition in chronic heart failure: A double-blind,					
		placebo-controlled study of Imidapril." J. Am. Coll. Cardiol. 32: 1811-8 (1998).	-				
			1:				
	A65	Venugopal, "Cardiac natriuretic peptides – hope or hype?" J. Clin. Pharm. Ther. 26: 15-31, (2001).					
			-				
l							
	100		<u> </u>				
. \	A66	Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from					
•		Escherichia coli." Nature 341:544-546, (1989).					
LYL			:				
•							
•							

	///		
Examiner Signature	LK.	Date Considered	7/19/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 2Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

OTP E

HDV 1 2 2003

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, Roumber.

erwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B	PTO CHADENAR	·	Complet if Known	
	INFORMATION DI			Application Number	10/419,059	
	STATEMENT BY A	APPLI	CANT	Filing Dat	04/17/2003	
				First Nam d Inv ntor	Kenneth F. Buechler	***************************************
				Group Art Unit	Unassigned	
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned	
Sheet	. 8	of	8	Attorney Docket Number	071949-7001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cit Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	176
171	A67	Wilson, "Simplified conjugation chemistry for coupling peptides to F(ab') fragments; autologous red cell	
216	•	agglutination assay for HIV-1 antibodies." J. Immunol. Methods 175:267-273, (1994).	
.			-
	A68	Wright et al., "Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a	1
		novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures."	
		Prostate Cancer and Prostatic Diseases 2: 264-76, (1999).	1:
	:		
	A69	Yarmush, "Coupling of antibody-binding fragments to solid-phase supports: site-directed binding of F(ab')2	
LYL		fragments." J. Biochem. Biophys. Methods 25:85-97, (1992).	
0,0			

Examiner Signature	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English tanguage Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

winder.				·		
	Substitute for	form 1449B/	SILE AS		Complete if Known	
	INFORMATIO	N DISCLØS	SURE \$\	Application Number	10/645,874	:
	STATEMENT	BY APPLIC	CANT 1 2004 W	Filing Date	08/20/2003	
		∵ '{ `	HON S & TOPA S	First Named Inventor	Buechler et al.	
		\-		Group Art Unit	1645	
	(use as many sh	neets as ned		Examiner Name		
Sheet	.1	of	TRABE	Attorney Docket Number	071949-7002	

				U.S. PATENT DOCUMENTS	5	
Examiner Initials*	2	U.S. Patent	Document	Name of Details and the	Date of Publication of	Pages, Columns, Lines,
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
LYL	A1	5352587		Chang et al.	10-04-1994	
LYL	A2	5422393		Bricker et al.	06-06-1995	
			 			
			1			

				F	OREIGN PATENT DOCUMEN	rs		
Examiner Initials*	Cite No. ¹	Fore Office ³	eign Patent D Number ⁴	locument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76
		•						

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
	A3	International Search Report and the Written Opinion of the International Searching Authority from PCT Application No. PCT/US04/12024.	1
			:
			·
			:

	·/			
Examiner Signature		Date Considered	7/11/06	:

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.				\overline{x}			
	Substitute for	r form 1449B	/PTQ	7	a	Complete if Known	
	INFORMATIO	ON DISCLO	SUBSE 44		Application Number	10/645,874	
	STATEMENT	BY APPLI	CÆNT '₹		Eiling Date	08/20/2003	
	Date Submitted	d. January 2	on whos	de la	Errst Named Inventor	Buechler	
				•	Consum And I Imid	1743	
	(use as many s	heets as ne	cessar	سرد/ <u>ر</u>	Examiner Name		
Sheet	1	of	1	, .	Attomey Docket Number	071949-7002	

. U.S. PATENT DOCUMENTS											
Examiner Initials*		U.S. Patent	Document .		Date of Publication of	Pages, Columns, Lines, Where Relevant					
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document . MM-DD-YYYY	Passages or Relevant Figures Appear					
LYL	A1	5786163		Hall	07-28-1998						
LYL	A2	6627457		Pandian et al.	09-30-2003						
LYL	A3	6670138		Gonzalez-Zulueta et al.	12-30-2003						
											

			***************************************	F	REIGN PATENT DOCUMEN	TS		1
Examiner Initials*	Cite No.1	Fore Office ³	oign Patent C Number ⁴	Occument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	T6
								1

		NON PATENT LITERATURE DOCUMENTS	:
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т6
LYL	A4	Huttunen et al., "Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. The Journal of Biological Chemistry, 275:40096-40105, 2000.	
LYL	A5	Mussack et al., Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisma. Resuscitation, 49:193-199, 2001.	:
LYL	A6	Yakoviev et al., Activation of CPP32-Like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. The Journal of Neuroscience, 17(19): 7415-724, 1997.	
4	Α7	International Search Report for international application No. PCT/US04/20984	
-	A8	Notice of References Cited, PTO-892, Part of Paper No. 2004 1202 from U.S. Application No. 10/225,082 filed August 20, 2002.	

Examiner Signature	XX	Date Considered	7/19/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE · Under the Reperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	PROPRIES for f	orm 1449B	/PTO	Complete if Known					
	INFORMATION	DISCLO	SURE	Application Number	10/645,874				
	STATEMENT I	BY APPLI	CANT	Filing Date	08/20/003				
				First Named Inventor	Kenneth F. Buechler				
				Group Art Unit	1646				
(use as many sheets as necessary)				Examiner Name					
Sheet	1	of	1	Attomey Docket Number	071949-7002	:			

				U.S. PATENT DOCUMENTS	3	-
Examiner Initials*	Cite No. ¹	U.S. Patent	Document	Name of October on Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
CYL	A1	6756483		Bergmann et al.	06-29-2004	
LYL	A2	6828107		Asada et al.	12-07-2004	
			 			

				 F(DREIGN PATENT DOCUMEN	TS		:
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
								1
							,	
				 				1
ł		1		1				1.

		NON PATENT LITERATURE DOCUMENTS	:					
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
		·						

		·	:
Examiner Signature	K/L	Date Considered	7/19/06

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique cliation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

P Substitute for	form 1449B/PTO		Complete if Known			
INFORMATIO	N DISCLOSURE	Application Number	10/645,874			
/ STATEMENT	BY APPLICANT	Filing Date	8/20/2003			
SEP 0 6 2005 W		First Named Inventor	Kenneth F. Buechler			
(use as ready sheets as necessary)		Group Art Unit	1645			
		Examiner Name				
Sheet TRADEMARK	of 1	Attorney Docket Number	071949-7002			

	U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant			
	Cite No.1	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear			

		·		F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Kind Code ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
								1
					_			
	•						,	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CYU	A1	Harter et al., Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury. Journal of Neuroimmunology, 121:76-78, 2001.	
		·	
			ŀ

		·
Examiner Signature	Date Considered	7/14/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.			OF			
	Substitute for fo	m 14498/	PTØ 0 4	a \	Complete if Known	
			/ .	Papplication Number	10/645,874	
	INFORMATION	DISCLO	SURE _{LCC 0} 8 2003	நிling Date	8/20/2003	
	STATEMENT B	Y APPLI	SUREDEC 0 8 2005	्री irst Named Inventor	Kenneth F. Buechler	
			\ -	455	1645	
	(use as many she	ets as ne	cessal maneu	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	071949-7002	

				U.S. PATENT DOCUMENTS	;	
Examiner Initials*		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Cite No. ¹	Number	Kind Code ² (if known)		Cited Document MM-DD-YYYY	
CYL	A1	5,206,140		Marder et al.	04-27-1993	
LYL	A2	6,309,888		Holvoet et al.	10-30-2001	
LYL	A3	6,461,828		Stanton et al.	10-08-2002	

			U.S	. PATENT APPLICATION DOCU	MENTS				
Examiner Initials*	Cite No. ¹	Cito	Cite	2:0	U.S. Patent Ap Docume	•	Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant
		Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document		Passages or Relevant Figures Appear			

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	For Office ³	eign Patent C Number ⁴	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
								1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ°
LYL	A4	FONAROW et al., "Combining Natriuretic Peptides and Necrosis Markers in Determining Prognosis in Heart Failure," Reviews in Cardiovascular Medicine, 2003, Suppl. 4, Vol. 4	
LYL	A5	RICHARDS et al., "Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction," Heart, 1999, pp. 114-120, Vol. 81	:
LYC	A6	SAADY et al., "Left appendage: structure function, and role in thromboembolism," Heart, 1999, pp. 547-555, Vol. 82	

Examiner Signature	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Petent Documents. ³Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IAN 1 9 2006 Under the Paperwork Reduction Act of 1995 persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute Ortown	PSO/PTO	Complete if Known		
			Application Number	10/645,874	
	INFORMATION DISC	CLOSURE	Filing Date	8/20/2003	
	STATEMENT BY AF	PPLICANT	First Named Inventor	Kenneth F. Buechler	
			Group Art Unit	1743	
(use as many sheets as necessary)			Examiner Name	Unassigned	
Sheet	1	of 2	Attorney Docket Number	071949-7002	

U.S. PATENT DOCUMENTS								
Examiner Cite No. 1	0.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
						· "		

U.S. PATENT APPLICATION DOCUMENTS								
Examiner Initials*	Cita	U.S. Patent Application Document		Name of Detentor or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant		
	Cite No. ¹	Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

				FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	Fo Office ³	oreign Patent (Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T®
LYL	A1	wo	02/083913		Biosite Diagnostics, Inc.	10-24-2002		
					·			<u> </u>

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	76
141	A2	CASSIN et al., È realizzabile una strategia operative piu efficace per la gestione in urgenza del paziente con dolore toracico acuto?, Ital Heart J Suppl, Feb. 2000, pp. 186-201, Vol. 1	
LYL	А3	FUTTERMAN et al., Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A, American Journal of Critical Care, March 2002, pp. 168-172, Vol. 11, No. 2	
LYL	A4	HUNT et al., Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment, Clinical Endocrinology, 1997, pp. 287-296, Vol. 47	1

	////		
Examiner Signature	$\mathcal{L}\mathcal{H}$	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute t	or form 144	19B/PTO		Complete if Known		
				Application Number	10/645,874		
INFORMATION DISCLOSURE				Filing Date	8/20/2003		
	STATEMEN	IT BY AP	PLICANT	First Named Inventor	Kenneth F. Buechler		
				Group Art Unit	1743		
(use as many sheets as necessary)			necessary)	Examiner Name	Unassigned		
Sheet	2		of 2	Attorney Docket Number	071949-7002		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶				
LYL	A5	SAGNELLA et al., Measurement and significance of circulating natriuretic peptides in cardiovascular disease, Clinical Science, Nov. 1998, pp. 519-529, Vol. 95, No. 5					
145	A6	SONEL et al., Prospective Study Correlating Fibrinopeptide A, Troponin I, Myoglobin, and Myosin Light Chain Levels with Early and Late Ischemic Events in Consecutive Patients Presenting to the Emergency Department with Chest Pain, Circulation, Sep. 5, 2000, pp. 1107-1113, Vol. 102, No. 10					
			:				
			:				
•							
	-						
	·						
		·					
			1				
			1				
			+-				

	///		·
Examiner Signature	L. L.	Date Considered	7/19/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ¹See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. number.

	Syperinted	14491 m	3/PTO	Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			DSURE	Application Number	10/645,874	•	
			.ICANT	Filing Date	08/20/2003		
			•	First Named Inventor	Kenneth F. Buechler		
				Group Art Unit	1743		
(use as many sheets as necessary)			ecessary)	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	. 071949-7002		

U.S. PATENT DOCUMENTS								
Examiner Cite No.1	C:4-	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
LYL	A1	2003/0022235		Dahlen et al.	01-30-2003			
LYL	A2	5,290,678		Jackowski	03-01-1994			
					·	;		
			l					

U.S. PATENT APPLICATION DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Application Document		Name of Patentee or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant		
		Serial Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

					FC	REIGN PATENT DOCUMEN	TS		-
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т6
									╁

	•	NON PATENT LITERATURE DOCUMENTS	:
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶

	///			
Examiner Signature		Date Considered	7/19/06	:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document, ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.